Immuno AG
Immuno AG was a major[1] pharmaceutical company founded in 1960 by Dr. Otto Schwarz & Dr. Hans Eibl[2] with headquarters in Vienna, Austria.[3]
In 1996 the company was acquired by Baxter for $715 million.[4]
Business
Immuno manufactured blood products including factor VIII and factor IX[5] such as Kryobulin and Krobulin TIM.[6]
Lawsuits
In 1983 Immuno sued Dr.
In 1986 two civil lawsuits were brought against Immuno by the Association Against Animal Experimentation in regard to treatment of chimpanzees.[9]
The plant in Krems, which was set up in 2002 but never went into operation, was subjected to an examination of its further usability in the course of 2013. The partial expansion was announced in autumn 2013: "In the first expansion stage, a production line is initially planned, and there is sufficient space for possible future expansions. The investment volume is estimated at 138 million euros. The start of construction is planned for the first quarter of 2014."[10]
References
- ISBN 9789400908017– via Google Books.
- ^ Stern, Joe. "In Memoriam of Dr. Otto Schwarz - Plasma Protein Therapeutics Association (PPTA)".
- ^ "Immuno AG".
- ^ Thomas M. Burton (30 August 1996). "Baxter Confirms Pact To Acquire Immuno". Wall Street Journal.
- ^ "Method of producing a factor-VIII(AHF)-high-concentrate".
- ^ "Final Report: Chapter 23 - Viral Inactivation of Blood Products for Haemophilia Therapy up to 1985".
- ^ "Abroad at Home; Abusing The Law". The New York Times. 10 May 1991.
- ^ "IMMUNO, A.G., APPELLANT, v. JAN MOOR-JANKOWSKI, RESPONDENT".
- ^ Information, Reed Business (21 August 1986). "New Scientist". Reed Business Information – via Google Books.
{{cite web}}:|first=has generic name (help) - ^ "Baxter Österreich - News & Medien - Pressemitteilungen - 2013 - Gesundheitsunternehmen Baxter investiert in Pharmaproduktion in Krems". 2014-05-06. Archived from the original on 2014-05-06. Retrieved 2022-08-19.